GrantPostedDiscretionary

Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

National Institutes of Health
RFA-TR-24-023
Application Deadline
Jun 2, 2026
74 days left
Days Remaining
74
Until deadline
Award Ceiling
$275,000
Total Program Funding

Grant Opportunity Analysis

The National Institutes of Health (NIH) is offering a funding opportunity for preclinical proof of concept studies focused on rare diseases through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established rare disease models to validate therapeutic agents, including small molecules and biologics, that address significant unmet medical needs. With approximately 30 million Americans affected by rare diseases, this funding opportunity seeks to bridge the gaps in drug development and propel promising agents towards clinical trials. Interested applicants can apply for a maximum budget of $275,000 over a two-year project period, with applications opening on May 3, 2024, and a close date of June 2, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-023.html.

Eligible Applicants

Others
Additional Eligibility Information

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Grant Documents

1 Files
RFA-TR-24-023.html
HTML113 KB8/24/2024
AI Summary
The National Institutes of Health (NIH) is issuing a funding opportunity for preclinical proof of concept studies targeting rare diseases through the R21 Exploratory/Developmental Research Grant mechanism. This initiative, designated as RFA-TR-24-023, aims to fund preclinical efficacy studies in established rare disease models. The goal is to demonstrate the viability of therapeutic agents, such as small molecules and biologics, that address significant unmet medical needs. Applications are encouraged from a diverse group of organizations and must include plans for collaboration with a rare disease steering committee. Key dates include an open date for applications starting May 3, 2024, with funding targeted at up to $1.2 million for 3-5 awards in FY 2025. Applications are restricted to non-clinical trial research and must demonstrate the readiness of therapeutic agents through prescribed evidence. The total project period is limited to two years with a maximum budget of $275,000. This funding opportunity recognizes the unique challenges in developing therapeutics for rare diseases, as approximately 30 million Americans are affected by such conditions. The program seeks to bridge funding gaps in drug development to propel promising agents towards clinical trials.

Related Grant Opportunities

Project Timeline

postedOriginal Opportunity PostedApr 3, 2024
deadlineApplication DeadlineJun 2, 2026
expiryArchive DateJul 8, 2026

Funding Details

Award Ceiling
$275,000
No cost sharing required

Agency & Classification

Agency
National Institutes of Health(HHS-NIH11)
Funding Category
Health
Funding Instrument
Grant

Grantor Contact

CFDA Numbers

93.350

Official Sources